• Home
  • Cardiovascular diseases Publications

Cardiovascular diseases Publications

Cardiovascular diseases Publications

  • Prescription behavior for gastroprotective drugs in new users as a result of communications regarding clopidogrel-proton pump inhibitor interaction.Abstract

    Safety concerns of the concomitant use of clopidogrel-proton pump inhibitors (PPIs) were published in 2009 and 2010 by the medicines regulatory agencies, including a direct healthcare professional communication. We examined the association between various safety statements and prescription behavior for gastroprotective drugs in naive patients in the Netherlands during the years 2008-2011

    Pharmacology Research & Perspectives. July 18; 4 (4): e00242.
  • Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.Abstract

    Analyses of healthcare data from 30 million individuals in three countries showed that current use of bisphosphonates may be associated with a small increased risk of cardiac valvulopathy (vs. those not exposed within the previous year), although cnfounding cannot be entirely ruled out. The observed tendency for decreased valvulopathy risk with cumulative duration of bisphosphonate use >6 months may even indicate a protective effect with prolonged use

    Coloma PM, deRidder M, Bezemer I, Herings RM, Gini R, Pecchioli S, Scotti L, Rijnbeek P, Mosseveld M, van der Lei J, Trifiro G, Sturkenboom M, Consortium Eu-Adr. Osteoporos Int. 2016 May; 27 (5): 1857-67.
  • Oral and inhaled corticosteroid use and risk of recurrent pulmonary embolism.Abstract

    INTRODUCTION: Chronic inflammatory diseases predispose for development of a first pulmonary embolism (PE). Previous studies showed that corticosteroids, which are the mainstay of treatment for inflammatory diseases, enhance the risk of a first venos thromboembolism. Yet, it is unknown whether corticosteroids also predispose for recurrent events

    Sneeboer MM, Hutten BA, Majoor CJ, Bel EH, Kamphuisen PW. Thromb Res. 2016 Feb 12; 140 46-50.
  • Explaining the Decline in Coronary Heart Disease Mortality in the Netherlands between 1997 and 2007.Abstract

    OBJECTIVE: We set out to determine what proportion of the mortality decline from 1997 to 2007 in coronary heart disease (CHD) in the Netherlands could be attributed to advances in medical treatment and to improvements in population-wide cardiovascuar risk factors. METHODS: We used the IMPACT-SEC model

    Koopman C, Vaartjes I, van Dis I, Verschuren WM, Engelfriet P, Heintjes EM, Blokstra A, Deeg DJ, Visser M, Bots ML, O'Flaherty M, Capewell S. PLoS One. 2016 11 (12): e0166139.
  • Anticoagulant Treatment after VTE in the Netherlands: A Retrospective Cohort Study.Abstract

    Background: The aim of the study was to describe initial anticoagulant treatment after venous thromboembolism (VTE) and relate this to the underlying risk factors, guidelines and recurrence rates.

    Bezemer ID, van den Berg EJ, Herings RMC, Bamber L, Penning-van Beest FJA, Folkerts K, Coppens M. J J Hemato. 2016 2 (2): 030.
  • Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study.Abstract

    OBJECTIVES: To investigate the cardiovascular safety of non-steroidal anti-inflammatory drugs (NSAIDs) and estimate the risk of hospital admission for heart failure with use of individual NSAIDs. DESIGN: Nested case-control study. SETTING: Five poplation based healthcare databases from four European countries (the Netherlands, Italy, Germany, and the United Kingdom)

    Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G, SafetyofNon-steroidalAnti-inflammatoryDrugsProject Consortium. BMJ. 2016 354 i4857.
  • Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?.Abstract

    BACKGROUND: Metformin, statin and aspirin use seem associated with decreased mortality in cancer patients, though, without adjusting for one another. Independent associations of these drugs with overall mortality after colorectal cancer (CRC) diagnsis within glucose-lowering drugs (GLDs) users were assessed

    Zander s MM, van Herk-Sukel MP, Vissers PA, Herings RM, Haak HR, van dePoll-Franse LV. Br J Cancer. 2015 Jul 28; 113 (3): 403-10.
  • High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events.Abstract

    AIMS: Intensive glucose control, often involving insulin treatment, failed to improve cardiovascular outcomes in several clinical trials. Observational studies reported an association between insulin use and cardiovascular disease (CVD) risk. It hatherefore been suggested that insulin adversely affects CVD risk

    Stoekenbroek RM, Rensing KL, BernelotMoens SJ, Nieuwdorp M, DeVries JH, Zwinder man AH, Stroes ES, Currie CJ, Hutten BA. Atherosclerosis. 2015 Mar 30; 240 (2): 318-323.
  • Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study.Abstract

    Preclinical data showed anticancer effects of statins in melanoma, but meta-analyses could not demonstrate a reduced melanoma incidence in statin users. Rather than preventing occurrence, statins might reduce growth and metastatic spread of melanoms and ultimately improve survival. In this population-based study, we investigated the relationship between statin use and survival of melanoma patients

    Livingstone E, Hollestein LM, van Herk-Sukel MP, van dePoll-Franse L, Joosse A, Schilling B, Nijsten T, Schaden dorf D, deVries E. Cancer Med. 2014 Oct; 3 (5): 1284-93.
  • beta-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.Abstract

    BACKGROUND: Results from preclinical and observational studies suggest that beta-adrenoreceptor inhibition might influence disease progression of melanoma. PATIENTS AND METHODS: Patients 18years with cutaneous melanoma (Breslow thickness >1mm) regitered in the Eindhoven Cancer Registry between January 1, 1998 and December 31, 2010, who were also registered with PHARMO record linkage system (RLS), were eligible

    Livingstone E, Hollestein LM, van Herk-Sukel MP, van dePoll-Franse L, Nijsten T, Schaden dorf D, deVries E. Eur J Cancer. 2013 Dec; 49 (18): 3863-71.